Life Science News

Strongbridge Biopharma (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the Company has entered into an agreement for Novo Nordisk to acquire the rights to MACRILEN (macimorelin) in the United States and Canada. MACRILEN is the first and only …

Strongbridge Biopharma (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the Company has entered into an agreement for Novo Nordisk to acquire the rights to MACRILEN (macimorelin) in the United States and Canada. MACRILEN is the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency (AGHD).

As quoted in the press release:

“We are proud to enter into this MACRILEN agreement with Novo Nordisk, a global leader in endocrinology, as it aligns with our strategic objective to maximize the potential of MACRILEN while we continue to prepare for the potential regulatory approval of RECORLEV™ (levoketoconazole),” said Matthew Pauls, president and chief executive officer of Strongbridge Biopharma. “The upfront payment and equity investment from Novo Nordisk will significantly strengthen the Company’s overall financial position and marks a tremendous step forward in Strongbridge’s continued evolution as a company dedicated to rare diseases,” Pauls added.

Click here to read the full press release.

MARKETS

Markets
TSX18729.66-104.50
TSXV602.35-13.59
DOW31037.68+69.86
S&P 5003845.08+13.69
NASD11361.85+39.61
ASX6594.50-34.80

COMMODITIES

Commodities
Gold1744.78+4.38
Silver19.36+0.17
Copper3.49+0.08
Palladium1930.50+14.50
Platinum864.00+8.00
Oil99.00+0.47
Heating Oil3.46+0.05
Natural Gas5.56+0.05

DOWNLOAD FREE REPORTS

×